Opinion|Videos|October 7, 2024
Exploring the Role of MOA and PDE4 Pathways in Pediatric Patients with Plaque Psoriasis
Author(s)Karan Lal, DO, MS, FAAD, Helen T Shin, MD
Key Takeaways
- PDE4 inhibitors modulate inflammatory responses by increasing intracellular cAMP levels, reducing pro-inflammatory cytokine production.
- These agents offer a targeted approach, potentially minimizing side effects compared to traditional therapies.
Panelists discuss how phosphodiesterase-4 (PDE4) inhibitors, with their ability to modulate inflammatory pathways, hold promise as therapeutic targets for immune-mediated diseases like pediatric plaque psoriasis, offering unique benefits by potentially reducing inflammation with a favorable safety profile for pediatric patients.
Advertisement
Video content above is prompted by the following:
- In light of the shifting treatment landscape, can you shed light on phosphodiesterase inhibitors-4 (PDE4), their nature, and why they hold promise as therapeutic targets for immune-mediated diseases like PP?
- How might its mechanism of action provide unique benefits for pediatric patients?
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott
3
Reviewing Type 2 Inflammation Through a Different Lens
4
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
5
